ArticleJournal of the American College of Cardiology2023
Early Outcomes of Adult Heart Transplantation From COVID-19 Infected Donors.
Article in Journal of the American College of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 23 citations in OpenAlex.
- Safety and 1-Year Outcomes After Transplanting Hearts From SARS-CoV-2 Positive Donors: Insights From an International Analysis.Immunity, inflammation and disease · 2025Article
- Expanding the Donor Pool.Methodist DeBakey cardiovascular journal · 2025Review
- Evolution of heart transplant donor characteristics in the 21World journal of transplantation · 2024Review
- Successful heart transplantation from a COVID-19-positive donor: A clinical case report.Clinical case reports · 2024Article
- One Year Outcomes Following Transplantation with COVID-19-Positive Donor Hearts: A National Database Cohort Study.Journal of cardiovascular development and disease · 2024Article
- Non-Standard Risk Donors and Risk of Donor-Derived Infections: From Evaluation to Therapeutic Management.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Acceptance of Organs from Deceased Donors With Resolved or Active SARS-CoV-2 Infection: A Survey From the Council of Europe.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- New Scenarios in Heart Transplantation and Persistency of SARS-CoV-2 (Case Report).Life (Basel, Switzerland) · 2023Article
- Heart Transplant: Challenge Accepted.Journal of the American College of Cardiology · 2023Article
- Comparative 3-Year Allograft Outcomes for Recipients of Kidneys From SARS-CoV-2 NAT-Positive Donors.Transplant infectious disease : an official journal of the Transplantation SocietyArticle
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is a paucity of data on heart transplantation (HT) using COVID-19 donors.
objectivesThis study investigated COVID-19 donor use, donor and recipient characteristics, and early post-HT outcomes.
methodsBetween May 2020 and June 2022, study investigators identified 27,862 donors in the United Network for Organ Sharing, with 60,699 COVID-19 nucleic acid amplification testing (NAT) performed before procurement and with available organ disposition. Donors were considered "COVID-19 donors" if they were NAT positive at any time during terminal hospitalization. These donors were subclassified as "active COVID-19" (aCOV) donors if they were NAT positive within 2 days of organ procurement, or "recently resolved COVID-19" (rrCOV) donors if they were NAT positive initially but became NAT negative before procurement. Donors with NAT-positive status >2 days before procurement were considered aCOV unless there was evidence of a subsequent NAT-negative result ≥48 hours after the last NAT-positive result. HT outcomes were compared.
resultsDuring the study period, 1,445 "COVID-19 donors" (COVID-19 NAT positive) were identified; 1,017 of these were aCOV, and 428 were rrCOV. Overall, 309 HTs used COVID-19 donors, and 239 adult HTs from COVID-19 donors (150 aCOV, 89 rrCOV) met study criteria. Compared with non-COV, COVID-19 donors used for adult HT were younger and mostly male (∼80%). Compared with HTs from non-COV donors, recipients of HTs from aCOV donors had increased mortality at 6 months (Cox HR: 1.74; 95% CI: 1.02-2.96; P = 0.043) and 1 year (Cox HR: 1.98; 95% CI: 1.22-3.22; P = 0.006). Recipients of HTs from rrCOV and non-COV donors had similar 6-month and 1-year mortality. Results were similar in propensity-matched cohorts.
conclusionsIn this early analysis, although HTs from aCOV donors had increased mortality at 6 months and 1 year, HTs from rrCOV donors had survival similar to that seen in recipients of HTs from non-COV donors. Continued evaluation and a more nuanced approach to this donor pool are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.